Laura Mauri

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:2440-7. 2006
  2. doi request reprint Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients
    Alanna Coolong
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 117:790-7. 2008
  3. doi request reprint 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation
    Laura Mauri
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 62:317-28. 2013
  4. doi request reprint Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site
    Laura Mauri
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 162:826-31. 2011
  5. ncbi request reprint Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison
    Laura Mauri
    Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02116, USA
    Circulation 111:3435-42. 2005
  6. ncbi request reprint The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial
    Laura Mauri
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1442-9. 2007
  7. doi request reprint Drug-eluting or bare-metal stents for acute myocardial infarction
    Laura Mauri
    Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 359:1330-42. 2008
  8. ncbi request reprint Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials
    Laura Mauri
    Brigham and Women s Hospital, Boston, MA 02116, USA
    Circulation 112:2833-9. 2005
  9. pmc Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts
    Laura Mauri
    MSc, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 118:1817-27. 2008
  10. doi request reprint Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents
    Laura Mauri
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    JACC Cardiovasc Interv 3:1240-9. 2010

Detail Information

Publications64

  1. ncbi request reprint Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 48:2440-7. 2006
    ..This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES)...
  2. doi request reprint Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients
    Alanna Coolong
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 117:790-7. 2008
    ..Although MACE rates are reduced significantly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefit provided by EPDs has been well characterized...
  3. doi request reprint 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation
    Laura Mauri
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 62:317-28. 2013
    ..This study sought to evaluate 4-year outcomes of percutaneous repair versus surgery for mitral regurgitation...
  4. doi request reprint Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site
    Laura Mauri
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 162:826-31. 2011
    ..There have been no randomized trials evaluating whether cardiac surgery services on-site are essential for patient safety and optimal outcomes during and after PCI...
  5. ncbi request reprint Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison
    Laura Mauri
    Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02116, USA
    Circulation 111:3435-42. 2005
    ..Early evaluations of new stents have used continuous end points that are presumed surrogates for restenosis, but the generalizability and power of such end points have not been examined systematically...
  6. ncbi request reprint The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial
    Laura Mauri
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1442-9. 2007
    ....
  7. doi request reprint Drug-eluting or bare-metal stents for acute myocardial infarction
    Laura Mauri
    Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 359:1330-42. 2008
    ..Studies comparing percutaneous coronary intervention (PCI) with drug-eluting and bare-metal coronary stents in acute myocardial infarction have been limited in size and duration...
  8. ncbi request reprint Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials
    Laura Mauri
    Brigham and Women s Hospital, Boston, MA 02116, USA
    Circulation 112:2833-9. 2005
    ..We hypothesized that mean in-stent late loss might be a more stable estimator of restenosis propensity across such studies...
  9. pmc Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts
    Laura Mauri
    MSc, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 118:1817-27. 2008
    ..We sought to compare the clinical outcome of patients treated with DES with that of BMS...
  10. doi request reprint Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents
    Laura Mauri
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    JACC Cardiovasc Interv 3:1240-9. 2010
    ..This study sought to evaluate the long-term safety of the zotarolimus-eluting stent (ZES) using a pooled analysis of pivotal trials...
  11. doi request reprint Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial)
    Laura Mauri
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 161:807-14. 2011
    ..We describe a clinical trial to evaluate a DES with a novel polymer that may improve the antirestenosis effectiveness while maintaining the safety standards of currently Food and Drug Administration-approved DES...
  12. ncbi request reprint Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped?
    Alanna Coolong
    Department of Medicine, The Division of Cardiovascular Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Curr Cardiol Rep 8:267-71. 2006
    ..This article reviews the data presently available regarding pretreatment with clopidogrel before PCI, and the strength of evidence supporting long-term dual antiplatelet therapy...
  13. ncbi request reprint Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents
    Laura Mauri
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 95:1140-5. 2005
    ..Longer stent-to-lesion length strategies should be used only when a shorter stent is likely to result in incomplete lesion coverage and edge dissection, a strong determinant of stent thrombosis...
  14. doi request reprint Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Am J Cardiol 106:774-9. 2010
    ..In conclusion, restenosis requiring TLR was associated with an increased risk of cardiac death or MI occurring at TLR and during the subsequent 5 years...
  15. ncbi request reprint Stent thrombosis in randomized clinical trials of drug-eluting stents
    Laura Mauri
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 356:1020-9. 2007
    ..Definitions of stent thrombosis that have been used in clinical trials of drug-eluting stents have been restrictive and have not been used in a uniform manner...
  16. doi request reprint Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry
    Pallav Garg
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 118:2277-85, 7p following 2285. 2008
    ..We report on a large consecutive series of patients with DM followed up for 3 years after DES and BMS from a regional contemporary US practice with mandatory reporting...
  17. doi request reprint In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 2:767-75. 2009
    ..The aim of this study was to compare outcomes among unselected patients undergoing percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting stents (PES)...
  18. doi request reprint A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention
    Jason H Wasfy
    Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Circ Cardiovasc Qual Outcomes 6:429-35. 2013
    ..We aimed to develop and validate prediction models to assist clinicians and hospitals in identifying patients at highest risk for 30-day readmission after PCI...
  19. ncbi request reprint Effects of stent length and lesion length on coronary restenosis
    Laura Mauri
    Division of Clinical Biometrics, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 93:1340-6, A5. 2004
    ..This analysis supports a conservative approach of matching stent length to lesion length to reduce the risk of restenosis with bare metal stents...
  20. doi request reprint Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry
    David M Charytan
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Kidney Dis 57:202-11. 2011
    ..Patients with chronic kidney disease have been under-represented in randomized trials of drug-eluting stents relative to bare-metal stents and are at high risk of mortality...
  21. doi request reprint Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials)
    Pallav Garg
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 106:1436-42. 2010
    ..The effectiveness of SESs in decreasing restenosis compared to BMSs in patients with moderate RI was preserved and rates of death and myocardial infarction were not adversely affected...
  22. doi request reprint Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: a model for protection from acute myocardial infarction
    Cathy Jeon
    Lahey Clinic, Burlington, MA, USA
    Am Heart J 160:195-201. 2010
    ..We hypothesized that insertion sites of bypass grafts are located distal to sites of acute thrombosis and consequently decrease cardiac morbidity and mortality associated with plaque rupture...
  23. ncbi request reprint Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients
    David Charytan
    Renal Division, Center for Clinical Biometrics, Brigham and Women s Hospital, Boston, MA 02120, USA
    Am J Kidney Dis 49:409-16. 2007
    ....
  24. doi request reprint Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention
    Robert W Yeh
    MSc, Cardiology Division, GRB 800, Massachusetts General Hospital, Boston, MA 02144
    Circulation 124:1557-64. 2011
    ..To assist physicians in targeting DES use in patients at the highest risk for target vessel revascularization (TVR), we developed and validated a model to predict TVR...
  25. doi request reprint Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention
    Robert W Yeh
    Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Circ Cardiovasc Interv 5:227-36. 2012
    ..Little is known about variation in the performance of hospitals on this measure, and whether high hospital rates of readmission after PCI are due to modifiable deficiencies in quality of care has not been assessed...
  26. doi request reprint Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting
    Riya Chacko
    Department of Medicine and Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    JACC Cardiovasc Interv 2:498-503. 2009
    ..We sought to compare patient-oriented outcomes related to target vessel or nontarget vessel events for sirolimus-eluting stents (SES) versus bare-metal stents...
  27. doi request reprint Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary
    Laura Mauri
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 160:1035-41, 1041.e1. 2010
    ..Although current clinical practice guidelines recommend 12-month treatment after drug-eluting stent placement, even longer durations may prevent thrombotic events...
  28. ncbi request reprint Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents
    Laura Mauri
    Brigham and Women s Hospital, Boston, Mass 02116, USA
    Circulation 111:321-7. 2005
    ..Observed rates of restenosis after drug-eluting stenting are low (<10%). Identification of a reliable and powerful angiographic end point will be useful in future trials...
  29. doi request reprint Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents
    Jeffrey J Popma
    Department of Internal Medicine, Cardiology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circ Cardiovasc Interv 2:133-9. 2009
    ..We sought to identify the incidence of sidebranch occlusion during zotarolimus-eluting stent (ZES) and paclitaxel-eluting stent (PES) placement and to relate sidebranch occlusion to the occurrence of periprocedural MI...
  30. ncbi request reprint Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study)
    Alexis Matteau
    Brigham and Women s Hospital, Boston, Massachusetts
    Am J Cardiol 113:1146-52. 2014
    ..As HD ASA may be associated with adverse events in the setting of dual antiplatelet therapy, reducing local practice variation in the dose of ASA may be a target for quality improvement. ..
  31. doi request reprint Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease
    David M Charytan
    Renal Division and Clinical Biometrics, Department of Medicine, Brigham and Women s Hospital, 1620 Tremont Street, 3rd Floor, Boston, MA 02120, USA
    Clin Exp Nephrol 17:232-9. 2013
    ....
  32. doi request reprint The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation
    Laura Mauri
    Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 160:23-9. 2010
    ..Whether an endovascular approach to repair can offer comparable effectiveness with improved safety remains to be determined in randomized trials...
  33. ncbi request reprint Clinical end points in coronary stent trials: a case for standardized definitions
    Donald E Cutlip
    Harvard Clinical Research Institute, Harvard Medical School, 930 Commonwealth Avenue, Boston, MA 02215, USA
    Circulation 115:2344-51. 2007
    ..Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation...
  34. doi request reprint Nonemergency PCI at hospitals with or without on-site cardiac surgery
    Alice K Jacobs
    Boston University School of Medicine, Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston, MA 02118, USA
    N Engl J Med 368:1498-508. 2013
    ..Emergency surgery has become a rare event after percutaneous coronary intervention (PCI). Whether having cardiac-surgery services available on-site is essential for ensuring the best possible outcomes during and after PCI remains uncertain...
  35. doi request reprint Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients
    Neil J Wimmer
    Brigham and Women s Hospital, and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
    Stroke 43:3218-24. 2012
    ..The aim of this study was to predict individual patient risk after carotid artery stenting in patients at higher risk for carotid endarterectomy...
  36. ncbi request reprint An evidence-based approach to the use of drug-eluting stents in clinical practice
    Richard E Kuntz
    Division of Clinical Biometrics, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02115, USA
    Am Heart Hosp J 2:132-41. 2004
    ....
  37. ncbi request reprint Devices for distal protection during percutaneous coronary revascularization
    Laura Mauri
    Brigham and Women s Hospital, Harvard Clinical Research Institute, Boston, MA, USA
    Circulation 113:2651-6. 2006
  38. pmc Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention
    Neil J Wimmer
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Am Heart Assoc 2:e000174. 2013
    ..We sought to develop a prediction model for access site complications in patients undergoing PCI with femoral arteriotomy, and assess whether transradial access was selectively used in patients at high risk for complications...
  39. doi request reprint Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy
    Paul A Grayburn
    Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas, TX P A G University of California, San Francisco E F Abbott Vascular Structural Heart, Menlo Park, CA C S MedStar Health Research Institute, Washington, DC N J W Boston University School of Public Health, Harvard Clinical Research Institute, Boston, MA J M Duke University Medical Center, Durham, NC D G G Evanston Hospital, NorthShore University Health System, Evanston, IL T F and Brigham and Women s Hospital, Harvard Clinical Research Institute, Harvard Medical School, Boston, MA L M
    Circulation 128:1667-74. 2013
    ..Therefore, an analysis was performed to evaluate the relationship between MR reduction and LV and LA volumes after MitraClip therapy...
  40. doi request reprint Rationale and design of the DeFACTO (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiOgraphy) study
    James K Min
    Department of Medicine, Imaging, and Biomedical Sciences, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Cardiovasc Comput Tomogr 5:301-9. 2011
    ....
  41. doi request reprint Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice
    Amit P Amin
    Cardiovascular Division, Department of Medicine, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, Missouri, USA
    Arch Intern Med 172:1145-52. 2012
    ..Our objective was to assess whether DES are preferentially used in patients with higher predicted TVR risk and to estimate if lower use of DES in low-TVR-risk patients would be more cost-effective than the existing DES use pattern...
  42. doi request reprint Causes of short-term readmission after percutaneous coronary intervention
    Jason H Wasfy
    From the Cardiology Division J H W, C O B, R W Y, Department of Medicine J H W, C O B, R W Y, J B S, and Laboratory of Computer Science A H Z, J L, Massachusetts General Hospital, Harvard Medical School, Boston Saint Luke s Mid America Heart Institute UMKC, Kansas City, MO K F K, J A S Department of Biostatistics, Harvard School of Public Health, Boston, MA K Z, S L T N Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA L M and Harvard Clinical Research Institute, Boston, MA L M, R W Y
    Circ Cardiovasc Interv 7:97-103. 2014
    ..Rehospitalization within 30 days after an admission for percutaneous coronary intervention (PCI) is common, costly, and a future target for Medicare penalties. Causes of readmission after PCI are largely unknown...
  43. doi request reprint Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials
    Moshe Vardi
    Harvard Clinical Research Institute, Boston, Massachusetts Cardiology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Catheter Cardiovasc Interv 82:1031-8. 2013
    ..To assess long-term outcomes of Endeavor Zotarolimus-eluting stent (E-ZES) implantation in patients with diabetes mellitus (DM)...
  44. ncbi request reprint Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial
    Laura Mauri
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 90:1079-83. 2002
    ..CB angioplasty should be reserved for difficult lesions in which controlled dilatation is believed to provide a better acute result compared with balloon angioplasty alone...
  45. ncbi request reprint The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients
    David Charytan
    Division of Clinical Biometrics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 152:558-64. 2006
    ....
  46. doi request reprint Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model
    Pallav Garg
    Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 51:1844-53. 2008
    ..We sought to define what incremental risk of very late stent thrombosis (VLST) in drug-eluting stents (DES) would outweigh the restenosis benefit...
  47. doi request reprint Location of acute coronary artery thromboses in patients with and without chronic kidney disease
    David M Charytan
    Renal Division and Clinical Biometrics, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Kidney Int 75:80-7. 2009
    ....
  48. ncbi request reprint Coronary artery spatial distribution of acute myocardial infarction occlusions
    John C Wang
    Division of Clinical Biometrics, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02116, USA
    Circulation 110:278-84. 2004
    ..We developed a spatial map of the distribution of acute coronary occlusions to test our hypothesis that plaque ruptures do not occur uniformly throughout the coronary tree...
  49. pmc Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?
    Neil J Wimmer
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA
    Am Heart J 168:103-9. 2014
    ..We sought to quantify the delay in reperfusion from transradial PCI ("transradial delay") that would need to be introduced to offset the potential mortality benefit of transradial PCI, compared with transfemoral, observed in RCTs...
  50. doi request reprint Instrumental variable analysis to compare effectiveness of stents in the extremely elderly
    Robert W Yeh
    Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA
    Circ Cardiovasc Qual Outcomes 7:118-24. 2014
    ..Instrumental variable methods identify variables associated with treatment allocation to perform adjusted comparisons that may overcome limitations of more traditional approaches...
  51. doi request reprint Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?
    Sripal Bangalore
    Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Clinical Research Institution, Boston, MA 02115, USA
    EuroIntervention 5:F43-8. 2009
    ..Finally, given a disappearing frame of reference, both careful angiographic and intravascular ultrasound assessments are helpful to delineate the varying contributions of recoil, remodelling, and neointima formation...
  52. doi request reprint Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry
    Sripal Bangalore
    Department of Medicine, Division of Cardiovascular Medicine, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
    Circ Cardiovasc Interv 4:463-73. 2011
    ..However, it is not known if this benefit is also present when UFH doses are more tightly controlled (as measured by activated clotting time, ACT)...
  53. ncbi request reprint Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models
    Kelly H Zou
    Children s Hospital Boston, Boston, MA, USA
    Circulation 115:654-7. 2007
  54. pmc CKD and coronary collateral supply in individuals undergoing coronary angiography after myocardial infarction
    David M Charytan
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
    Clin J Am Soc Nephrol 7:1079-86. 2012
    ..Whether a diminished supply of collaterals contributes to the high risk in CKD patients is uncertain...
  55. doi request reprint Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data
    Rahul Sakhuja
    Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA
    Annu Rev Med 61:215-31. 2010
    ....
  56. doi request reprint Lack of association between migraine headache and patent foramen ovale: results of a case-control study
    Pallav Garg
    Division of Cardiology, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 121:1406-12. 2010
    ..We sought to evaluate the assumption of an association between migraine headaches and the presence of PFO by use of a large case-control study...
  57. ncbi request reprint The conundrum of late and very late stent thrombosis following drug-eluting stent implantation
    Pallav Garg
    Division of Clinical Biometrics, Brigham and Women s Hospital, Harvard Medical School and Harvard Clinical Research Institute, Boston, Massachusetts 02115, USA
    Curr Opin Cardiol 22:565-71. 2007
    ....
  58. ncbi request reprint Surrogates, substudies, and real clinical end points in trials of drug-eluting stents
    Dean J Kereiakes
    J Am Coll Cardiol 45:1206-12. 2005
  59. ncbi request reprint Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery?
    Donald S Baim
    J Am Coll Cardiol 47:878-81. 2006
  60. ncbi request reprint Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial
    Marie Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    J Am Coll Cardiol 50:1299-304. 2007
    ..This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents...
  61. ncbi request reprint Letter by Kereiakes et al regarding article, "Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern"
    Dean J Kereiakes
    Circulation 116:e389; author reply e390. 2007
  62. doi request reprint Studies of drug-eluting stents: to each his own?
    Laura Mauri
    Circulation 117:2047-50. 2008
  63. ncbi request reprint Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART)
    Laura Mauri
    Swedish Hospital, Seattle, Wash, USA
    Am Heart J 145:847-54. 2003
    ..We report on a multicenter, randomized, blinded end point trial comparing rotational atherectomy with balloon angioplasty in the prevention of restenosis of obstructed small coronary arteries...
  64. ncbi request reprint Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study
    Barry T Katzen
    Baptist Cardiac and Vascular Institute, Miami, Florida, USA
    Catheter Cardiovasc Interv 70:316-23. 2007
    ....